Google
ASRT — ASSERTIO THERAPEUTICS INC (Healthcare >> Drug Manufacturers - Specialty & Generic)
ASRT FAQ
What is ASRT's P/E ratio?
ASSERTIO THERAPEUTICS INC (ASRT) currently trades at a P/E ratio of 13.24.
What is ASRT's ROE?
ASSERTIO THERAPEUTICS INC reports a Return on Equity (ROE) of -47.19%.
What is ASRT's dividend yield?
ASSERTIO THERAPEUTICS INC offers a dividend yield of 0.00%.
What is ASRT's Deepscope Quality Score?
Deepscope rates ASRT's overall financial quality at 8 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ASRT?
Deepscope's AI Timing Score for ASRT is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ASRT belong to?
ASSERTIO THERAPEUTICS INC is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange.
|
USD 23.45
Price
-0.01
(-0.04%)
Day Change
|
|
|---|
ASRT, the overall quality is not good ( Quality = 8) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 90 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 23.45 |
| PBV / Sector |
2.00 / 2.65
|
| Earning Per Share | -5.52 |
| PE / Sector |
13.24 / 22.84
|
| PEG or PE/Growth / Sector |
-0.10 / 0.11
|
| Average 1M Daily Value |
7.39 M
|
| Average 1W Daily Value |
4.99 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-05 09:12:39 |
| Symbol | ASRT |
| Name | ASSERTIO THERAPEUTICS INC |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 6.46 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 151.54 / 9,638.91 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 100 South Saunders Road, Lake Forest, IL, United States, 60045
Phone: 224 419 7106
Website: https://www.assertiotx.com
Employees: 53
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
